Combined therapy of xenografts of human pancreatic carcinomas with rTNF-alpha and mitomycin C.
Based on previously published experimental studies in nude mice indicating that rTNF-alpha as well as mitomycin C are able to induce significant growth inhibition of xenotransplants of gastrointestinal and pancreatic carcinomas we have investigated the antitumor effects of rTNF-alpha (0.8 mg/kg daily for 21 days) and mitomycin C (2.4 mg/kg once weekly, day 1, 7, 14) as single drugs and in combination (0.8 + 2.4) in nude mice bearing xenografts of 4 human pancreatic carcinomas and 1 colorectal cancer. Serum CA 19-9 was measured additionally to tumor growth rate. The results demonstrate that combined treatment is more effective compared to rTNF-alpha and mitomycin C alone. Combined therapy resulted in a significant inhibition of tumor growth in 3 of 5 xenografts and in decrease of tumor volume to less than 50% of the initial values in 2 of 5 tumors. The results support the concept that combinations of cytokines with cytostatics might be of value for treatment of gastrointestinal and pancreatic cancer in vivo.
Klapdor
R
R
I. Medical Department, University of Hamburg, FRG.
Franke
N
N
Bahlo
M
M
D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D015295:Antigens, Tumor-Associated, Carbohydrate; D008937:Mitomycins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D016685:Mitomycin